CORETOX® in Treatment of Post Stroke Upper Limb Spasticity (Phase3)
A Randomized, Double-blind, Active Drug Controlled, Multi-Center, Phase I/III Clinical Trial to Evaluate the Efficacy and Safety of CORETOX® in Treatment of Post Stroke Upper Limb Spasticity
Sponsor: Medy-Tox
A PHASE3 clinical study on Muscle Spasticity, this trial is completed. The trial is conducted by Medy-Tox and has accumulated 9 data snapshots since 2017. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
9 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Jan 2022 — Jul 2024 [monthly]
Completed PHASE3
-
Jan 2021 — Jan 2022 [monthly]
Completed PHASE3
▶ Show 4 earlier versions
-
Sep 2020 — Jan 2021 [monthly]
Completed PHASE3
-
Mar 2020 — Sep 2020 [monthly]
Completed PHASE3
-
Apr 2019 — Mar 2020 [monthly]
Completed PHASE3
Status: Recruiting → Completed
-
Oct 2017 — Apr 2019 [monthly]
Recruiting PHASE3
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Medy-Tox
For direct contact, visit the study record on ClinicalTrials.gov .